drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous anti-CD4 chimeric antigen receptor T-cell therapy: patient T cells are lentivirally transduced to express an anti-CD4 scFv (derived from humanized mAb ibalizumab) linked to a third-generation CAR with CD28 and 4-1BB co-stimulatory domains and a CD3ΞΆ activation domain; administered as a single IV dose after lymphodepleting chemotherapy to target and eliminate CD4+ leukemic blasts.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally transduced to express an anti-CD4 scFv-based third-generation CAR (CD28 and 4-1BB costimulatory domains with CD3zeta signaling). After lymphodepletion and IV infusion, the CAR T cells bind CD4 on leukemic blasts, triggering activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CD4+ cells. Expected on-target effect includes depletion of normal CD4 T cells (T-cell aplasia).
drug_name
CD4CAR
nct_id_drug_ref
NCT06197672